Bioavailability of clobetasol propionate in different vehicles

Skin Pharmacology and Applied Skin Physiology

Volumn 16, Issue 4, 2003, Pages 212-216

  Franz, T J ^a   Lehman, P A ^b   Feldman, Steven R ^c   Spellman, M C ^a  

^a Bradley Pharmaceuticals Inc   (United States)

^b DermTech International   (United States)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Percutaneous absorption, clobetasol propionate; Psoriasis; Topical corticosteroids

Indexed keywords

CLOBETASOL PROPIONATE; SKIN CAP;

ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG FORMULATION; HUMAN; HUMAN TISSUE; MODEL; PRIORITY JOURNAL; SCALP; SKIN ABSORPTION;

ADMINISTRATION, CUTANEOUS; ANTI-INFLAMMATORY AGENTS; BIOLOGICAL AVAILABILITY; CLOBETASOL; EXCIPIENTS; GLUCOCORTICOIDS; HUMANS; SCALP; SKIN; SKIN ABSORPTION; VEHICLES;

EID: 0038016935     PISSN: 14222868     EISSN: None     Source Type: Journal    
DOI: 10.1159/000070843     Document Type: Article

References (14)

1. Feldman SR, Fleischer AB, Cooper JZ: New topical treatments change the pattern of treatment of psoriasis: Dermatologists remain the primary providers of this care. Int J Dermatol 2000;39:41-44.
2. Smith K: Skin Cap: What have we learned, and when did we learn it? Dermatol Online J 1997;3:11c.
3. Cruthfield CE 3rd, Lewis EJ, Zelickson BD: The highly effective use of topical zinc pyrithione in the treatment of psoriasis: A case report. Dermatol Online J 1997;3:3.
4. Stoughton RB: Are generic formulations equivalent to trade name topical glucocorticoids? Arch Dermatol 1987;123:1312-1314.
5. Franz TJ: Percutaneous absorption: On the relevance of in vitro data. J Invest Dermatol 1975;64:190-195.
6. Franz TJ: The finite dose technique as a valid in vitro model for the study of percutaneous absorption in man; in Simon GA, Paster Z, Klingberg MA, Kaye M (eds): Skin - Drug Application and Evaluation of Environmental Hazards. Basel, Karger, 1978, p 68.
7. Franz TJ, Parsell DA, Halualani RM, Hannigan JF, Kalbach JP, Harkonen WS: Betamethasone valerate foam 0.12%: A novel vehicle with enhanced delivery and efficacy. Int J Dermatol 1999;38:628-632.
8. Franz TJ, Parsell DA, Myers JA, Hannigan JF: Clobetasol propionate foam 0.05%: A novel vehicle with enhanced delivery. Int J Dermatol 2000;39:535-538.
9. Franz TJ, Lehman PA: The use of water permeability as a means of validation for skin integrity in in vitro percutaneous absorption studies. J Invest Dermatol 1990;94:525.
10. Housman TS, Keil KA, Mellen BG, McCarty MA, Fleischer AB Jr, Feldman SR: The use of 0.25% zinc pyrithione spay does not enhance the efficacy of clobetasol propionate 0.05% foam in the treatment of psoriasis. J Am Acad Dermatol, in press.
11. Burrows NP, Turnbull AJ, Punchard NA, Thompson RP, Jones RR: A trial of oral zinc supplementation in psoriasis. Cutis 1994;54:117-118.
12. Fleischer AB Jr, Feldman SR, Rapp SR, Reboussin DM, Exum ML, Clark AR: Alternative therapies commonly used within a population of patients with psoriasis. Cutis 1996;58:216-220.
13. Richards HL, Fortune DG, O'Sullivan TM, Main CJ, Griffiths CE: Patients with psoriasis and their compliance with medication. J Am Acad Dermatol 1999;41:581-583.
14. Olsen EA, Cram DL, Ellis CN, et al: A double-blind, vehicle-controlled study of clobetasol propionate 0.05% (Temovate) scalp application in the treatment of moderate to severe scalp psoriasis. J Am Acad Dermatol 1991;24:443-447.